+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery), by End Use (Hospitals, Clinics), and Segment Forecasts, 2019 - 2026

  • ID: 4871468
  • Report
  • October 2019
  • Region: Global
  • 120 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • F.Hoffmann-La Roche AG
  • GlaxoSmithKline Plc.
  • Grifols SA
  • Novartis
  • Pfizer, Inc.
  • MORE

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to this report. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressant's are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Further Key Findings From the Study Suggest:

  • Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
  • Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
  • North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
  • The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
  • Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Please Note: This report will be delivered within 2 business days of ordering.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc.
  • F.Hoffmann-La Roche AG
  • GlaxoSmithKline Plc.
  • Grifols SA
  • Novartis
  • Pfizer, Inc.
  • MORE
Chapter 1 Methodology and Scope

1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 Internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights

Chapter 3 Myasthenia Gravis Treatment Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.2 Market Restraint Analysis
3.4.3 Industry challenges
3.5 Myasthenia Gravis Treatment Market Analysis Tools
3.5.1 Industry analysis - Porter’s
3.5.1.1 Supplier Power
3.5.1.2 Buyer Power
3.5.1.3 Substitution Threat
3.5.1.4 Threat from new entrants
3.5.1.5 Competitive Rivalry
3.5.2 PESTEL Analysis
3.5.2.1 Political Landscape
3.5.2.2 Environmental Landscape
3.5.2.3 Social landscape
3.5.2.4 Technology landscape
3.5.2.5 Legal Landscape
3.5.3 Major deals and strategic alliances analysis
3.5.3.1 Joint ventures
3.5.3.2 Mergers and acquisitions
3.5.3.3 Licensing and partnership
3.5.3.4 Technology collaborations
3.5.3.5 Strategic Divestments
3.5.4 Market entry strategies

Chapter 4 Myasthenia Gravis Treatment Market - Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.4 Public Companies
4.4.1 Regional network map
4.4.2 Company market position analysis
4.4.3 Company market share, by region
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Company market position analysis
4.6 Supplier Ranking

Chapter 5 Myasthenia Gravis Treatment Market: Treatment Estimates and Trend Analysis
5.1 Definitions & Scope
5.2 Market Share Analysis, 2018 & 2026
5.3 Segment Dashboard
5.4 Global Myasthenia Gravis Treatment Market, by Treatment, 2015 to 2026
5.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
5.5.1 Medication MArket
5.5.1.1 Medication Market, 2015 to 2026 (USD Million)
5.5.2 Surgery Market
5.5.2.1 Surgery Market, 2015 to 2026 (USD Million)
5.5.3 Others MArket
5.5.3.1 Others Market, 2015 to 2026 (USD Million)

Chapter 6 Myasthenia Gravis Treatment Market: End Use Estimates and Trend Analysis
6.1 Definitions & Scope
6.2 Market Share Analysis, 2018 & 2026
6.3 Segment Dashboard
6.4 Global Myasthenia Gravis Treatment Market, by End Use, 2015 to 2026
6.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
6.5.1 Hospitals Market
6.5.1.1 Hospitals Market, 2015 to 2026 (USD Million)
6.5.2 Clinics Market
6.5.2.1 Clinics Market, 2015 to 2026 (USD Million)
6.5.3 Others MArket
6.5.3.1 Others Market, 2015 to 2026 (USD Million)

Chapter 7 Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis
7.1 Regional Market Snapshot
7.2 Regional Market Share and Leading Players, 2018
7.2.1 North America
7.2.2 Europe
7.2.3 Latin America
7.2.4 Asia Pacific
7.2.5 Middle East & Africa
7.3 Market Share Analysis by Country, 2018
7.3.1 North America
7.3.1.1 U.S.
7.3.1.2 Canada
7.3.2 Europe
7.3.2.1 UK
7.3.2.2 Germany
7.3.2.3 Spain
7.3.2.4 France
7.3.2.5 Italy
7.3.2.6 Russia
7.3.3 Latin America
7.3.3.1 Brazil
7.3.3.2 Mexico
7.3.3.3 Argentina
7.3.4 Asia Pacific
7.3.4.1 Japan
7.3.4.2 China
7.3.4.3 India
7.3.4.4 South Korea
7.3.4.5 Singapore
7.3.4.6 Australia
7.3.5 Middle East & Africa
7.3.5.1 South africa
7.3.5.2 Saudi Arabia
7.3.5.3 UAE
7.4 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.4.1 North America
7.4.2 Europe
7.4.3 Latin America
7.4.4 Asia Pacific
7.4.5 Middle East & Africa
7.5 Market Size & Forecasts, and Trend Analysis, 2018 to 2026
7.5.1 North America
7.5.1.1 North America Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.1.2 U.S.
7.5.1.2.1 U.S. Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.1.3 Canada
7.5.1.3.1 Canada Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2 Europe
7.5.2.1 Europe Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.2 UK
7.5.2.2.1 UK Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.3 Germany
7.5.2.3.1 Germany Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.4 Spain
7.5.2.4.1 Spain Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.5 France
7.5.2.5.1 France Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.6 Italy
7.5.2.6.1 Italy Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.2.7 Russia
7.5.2.7.1 Russia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.3 Latin America
7.5.3.1 Latin America Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.3.2 Brazil
7.5.3.2.1 Brazil Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.3.3 Mexico
7.5.3.3.1 Mexico Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.3.4 Argentina
7.5.3.4.1 Argentina Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4 Asia Pacific
7.5.4.1 Asia Pacific Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.2 Japan
7.5.4.2.1 Japan Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.3 China
7.5.4.3.1 China Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.4 India
7.5.4.4.1 India Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.5 South Korea
7.5.4.5.1 South Korea Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.6 Singapore
7.5.4.6.1 Singapore Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.4.7 Australia
7.5.4.7.1 Australia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.5 Middle East & Africa
7.5.5.1 Middle East & Africa Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.5.2 South Africa
7.5.5.2.1 South Africa Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.5.3 Saudi Arabia
7.5.5.3.1 Saudi Arabia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
7.5.5.4 UAE
7.5.5.4.1 UAE Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)

Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 Alexion Pharmaceutical Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Grifols SA
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Avadel Pharmaceuticals, Plc.
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Novartis
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Pfizer, Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 AbbVie Inc.
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 F.Hoffmann-La Roche AG
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 GlaxoSmithKline Plc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Bausch Health Companies Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Shire plc
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives

Full List of Figures and Tables Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3
  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals, Plc.
  • Novartis
  • Pfizer, Inc.
  • AbbVie Inc.
  • F.Hoffmann-La Roche AG
  • GlaxoSmithKline Plc.
  • Bausch Health Companies Inc.
  • Shire plc
Note: Product cover images may vary from those shown
Adroll
adroll